. 2020 Oct 26;23(5):498–508. doi: 10.4048/jbc.2020.23.e58

Table 4. Multivariate analysis of late recurrence risk according to serum 25(OH)D status after 5-year adjuvant endocrine therapy.

		All sites^a		Local^a		Regional LN^a		Bone^a		Visceral^a
		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Serum 25(OH)D status after 5-year adjuvant endocrine therapy
	Sufficient	1.000		1.000		1.000		1.000		1.000
	Deficient	2.284 (1.155–4.515)	0.018	2.195 (0.106–45.545)	0.611	17.453 (2.460–128.83)	0.005	2.394 (1.024–5.599)	0.044	2.735 (1.182–6.328)	0.019

25(OH)D = 25-hydroxyvitamin D; LN = lymph node; HR = hazard ratio; CI = confidence interval.

^aAdjusted for age, surgery, tumor size, number of axillary LN metastases, histologic grade, serum 25(OH)D status after 5-year adjuvant endocrine therapy, human epidermal growth factor receptor 2, Ki-67, lymphatic invasion, vascular invasion, and p53.